JERUSALEM, Jan. 27 (UPI) -- Teva said Friday it got some good news in its patent lawsuit involving a generic form of Aventis's allergy drug Allegra.
The Israeli company said a New Jersey District Court in its patent lawsuit over Allegra denied a motion for a preliminary injunction brought by Allegra sponsors Sanofi-Aventis Pharmaceuticals and Albany Molecular Research Inc.
The brand drug companies claim Teva is infringing a number of patents covering the antihistamine.
On Sept. 6, Teva and Rockville, Md.-based Barr Laboratories announced they had launched the generic drug, fexofenadine hydrochloride tablets in the United States.
The court's denial of the motion means it was not persuaded that Sanofi-Aventis was likely to prevail at trial.
Barr and Teva have already racked up other victories in the dispute, including the grant of a summary judgment of non-infringement with respect to three patents and a summary judgment of invalidity on an additional patent in the case last April, the company said.
Several patents remain in the litigation, but a trial date has not been set, Teva said.